Back Pain vs Fibromyalgia — Clinical Trial Comparison
Back Pain
Pain in the lower, mid, or upper back
Fibromyalgia
Widespread pain and central sensitisation
Back pain is the UK's leading cause of disability, affecting up to 80% of adults at some point. Fibromyalgia is a central pain syndrome causing widespread pain, fatigue, and cognitive difficulties. The two often overlap — back pain is the most common pain site in fibromyalgia patients. However, their underlying mechanisms, trial landscapes, and optimal treatment approaches differ significantly.
Key Differences at a Glance
| Feature | Back Pain | Fibromyalgia |
|---|---|---|
| Pain pattern | Localised to back/spine; may radiate to legs (sciatica) | Widespread — bilateral, above and below waist, axial skeleton |
| UK prevalence | ~80% lifetime prevalence; ~10–15% chronic at any time | ~2–4% of adults (~1.2–2.5 million) |
| Common causes | Mechanical (disc, muscle, joint), degenerative, postural, structural, neuropathic | Central sensitisation — amplified pain processing by the nervous system |
| Associated symptoms | Limited range of motion, muscle spasm, nerve symptoms (numbness, tingling) | Fatigue, unrefreshing sleep, brain fog, IBS symptoms, headache, anxiety/depression |
| Diagnostic imaging | Often shows structural changes (disc bulge, stenosis) — but these may not correlate with pain | Normal — fibromyalgia has no visible structural pathology on imaging |
| NICE approach | Exercise, CBT, manual therapy, NSAIDs; avoid opioids and bed rest | Exercise, CBT/ACT, amitriptyline, duloxetine, pregabalin; holistic management |
Clinical Trial Availability
| Trial Aspect | Back Pain | Fibromyalgia |
|---|---|---|
| UK trials actively recruiting | 30–50 studies | 15–25 studies |
| Most common trial phase | Phase 2–4 | Phase 2–3 |
| Top interventions tested | Physiotherapy approaches, spinal injections, cognitive functional therapy, regenerative medicine, digital health | Low-dose naltrexone, cannabinoids, neuromodulation, digital CBT, novel analgesics |
| Surgical trials | Significant (spinal fusion, disc replacement, decompression) | None — fibromyalgia is not treated surgically |
| Interventional trials | Major category (epidural injections, radiofrequency ablation, spinal cord stimulation) | Limited (TMS, tDCS, vagus nerve stimulation) |
| Psychological trials | Growing (CBT, ACT, pain education, cognitive functional therapy) | Major category (CBT, ACT, mindfulness, acceptance-based) |
Exciting Emerging Treatments
Back Pain Trials
- Cognitive functional therapy (CFT) — targeting pain beliefs and movement patterns together
- Regenerative medicine — platelet-rich plasma and stem cell injections for disc degeneration
- AI-guided physiotherapy — personalised exercise programmes adapted in real-time
- Spinal cord stimulation — next-generation devices with closed-loop technology for chronic neuropathic back pain
- Biopsychosocial digital programmes — apps combining exercise, education, and psychology
- Minimally invasive procedures — basivertebral nerve ablation for vertebrogenic pain
Fibromyalgia Trials
- Low-dose naltrexone (LDN) — modulating glial cell activation to reduce central sensitisation
- Medical cannabis and cannabinoids — THC:CBD formulations for widespread pain
- Transcranial magnetic stimulation (TMS) — non-invasive brain stimulation targeting pain networks
- Transcutaneous vagus nerve stimulation — portable devices modulating the vagus nerve
- Wearable-guided activity pacing — technology to optimise activity within pain thresholds
- Microdosing psilocybin — early research into serotonin-mediated pain modulation
💡 Not all back pain is mechanical — central sensitisation matters
If you've had back pain for years, seen multiple specialists, had normal imaging or findings that don't explain your pain level, and treatments haven't helped — your pain may be driven by central sensitisation (like fibromyalgia) rather than a structural problem. This distinction matters for trials: central sensitisation back pain responds to different treatments than mechanical back pain. Ask about this with your pain specialist.
Eligibility Differences
Back Pain Trial Criteria
- Pain location specified (lower back, mid-back, neck with radiation)
- Duration: chronic back pain trials typically require ≥ 3–6 months
- Pain mechanism: mechanical vs neuropathic vs nociplastic — trials target specific types
- Imaging requirements: some trials require MRI; others deliberately exclude those with structural findings
- Previous treatment failure may be required for interventional trials
Fibromyalgia Trial Criteria
- ACR 2016 fibromyalgia criteria met (widespread pain index + symptom severity scale)
- Exclusion of other rheumatic diseases that could explain symptoms (RA, lupus, ankylosing spondylitis)
- Pain severity thresholds (VAS ≥ 4, FIQR score requirements)
- Stable medication for 4–8 weeks before enrolment
- Co-existing back pain is common and usually doesn't exclude — but must be secondary to fibromyalgia
🔙 Back Pain Trials
Find actively recruiting back pain clinical trials across the UK
View Back Pain Trials⚡ Fibromyalgia Trials
Find actively recruiting fibromyalgia clinical trials across the UK
View Fibromyalgia Trials